Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.68 |
| ▸ | MMP9 | P14780 | 13/20 | 0.68 |
| ▸ | MMP3 | P08254 | 12/20 | 0.68 |
| ▸ | MMP13 | P45452 | 12/20 | 0.68 |
| ▸ | MMP1 | P03956 | 11/20 | 0.68 |
| ▸ | MMP7 | P09237 | 11/20 | 0.68 |
| ▸ | MMP14 | P50281 | 1/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690202 | 1.00 | MMP2 (0.68) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8283226 | 1.00 | MMP2 (0.68) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8283236 | 0.86 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL3615326 | 0.86 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1656896 | 0.86 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6723666 | 0.85 | MMP9 (0.72) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6723663 | 0.85 | MMP9 (0.72) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7347163 | 0.85 | MMP9 (0.72) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8283336 | 0.84 | MMP2 (0.91) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL27611876 | 0.84 | MMP2 (0.91) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7923446-B2 | 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis | WYETH LLC (US) | 2011-04-12 | — | — | US | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| CN-101583352-A | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2009-11-18 | — | — | CN | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1689380-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689716-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005060456-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATE DISEASE | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061459-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1623988-A | Biaryl sulfonamides and methods for using same | WYETH CORP (US) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP2 5/4885MMP9 14/4885MMP3 2/4885 |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | ADAMTS5, ADAMTS1, ADAMTS4 | MMP2 119/4885MMP9 87/4885MMP3 26/4885 |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | MMP2 5/4885MMP9 14/4885MMP3 2/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP2 5/4885MMP9 14/4885MMP3 2/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | MMP2 1/4885MMP9 2/4885MMP3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.